title: Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.
abstract: A series of derivatives of 2-anilino-5-phenyloxazole (5) has been identified as inhibitors of VEGFR2 kinase. Herein we describe the structure-activity relationship (SAR) of this novel template. Optimization of both aryl rings led to very potent inhibitors at both the enzymatic and cellular levels. Oxazole 39 had excellent solubility and good oral PK when dosed as the bis-mesylate salt and demonstrated moderate in vivo efficacy against HT29 human colon tumor xenografts. X-ray crystallography confirmed the proposed binding mode, and comparison of oxazoles 39 and 46 revealed interesting differences in orientation of 2-pyridyl and 3-pyridyl rings, respectively, attached at the meta position of the 5-phenyl ring.
authors.affiliation: GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709, USA. Philip.A.Harris@gsk.com
authors.forename: Philip A
authors.initials: PA
authors.lastname: Harris
authors.forename: Mui
authors.initials: M
authors.lastname: Cheung
authors.forename: Robert N
authors.initials: RN
authors.lastname: Hunter
authors.forename: Matthew L
authors.initials: ML
authors.lastname: Brown
authors.forename: James M
authors.initials: JM
authors.lastname: Veal
authors.forename: Robert T
authors.initials: RT
authors.lastname: Nolte
authors.forename: Liping
authors.initials: L
authors.lastname: Wang
authors.forename: Wendy
authors.initials: W
authors.lastname: Liu
authors.forename: Renae M
authors.initials: RM
authors.lastname: Crosby
authors.forename: Jennifer H
authors.initials: JH
authors.lastname: Johnson
authors.forename: Andrea H
authors.initials: AH
authors.lastname: Epperly
authors.forename: Rakesh
authors.initials: R
authors.lastname: Kumar
authors.forename: Deirdre K
authors.initials: DK
authors.lastname: Luttrell
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Stafford
mesh_terms: D000255:Adenosine Triphosphate / Q000737:chemistry; D020533:Angiogenesis Inhibitors / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D000814:Aniline Compounds / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D001665:Binding Sites; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D018360:Crystallography, X-Ray; D004285:Dogs; D006801:Humans; D008024:Ligands; D008297:Male; D051379:Mice; D008958:Models, Molecular; D010080:Oxazoles / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012995:Solubility; D013329:Structure-Activity Relationship; D014471:Umbilical Veins / Q000166:cytology; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors* / Q000737:chemistry; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D000814:Aniline Compounds; D008024:Ligands; C499144:N,5-diphenyl-1,3-oxazol-2-amine; D010080:Oxazoles; D042461:Vascular Endothelial Growth Factor A; D000255:Adenosine Triphosphate; D040301:Vascular Endothelial Growth Factor Receptor-2